Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Date:3/20/2009

boplatin are delivered to patients with escalating intravenous dosages of REOLYSIN(R). Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The second component of the trial is a Phase II, 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.

An independent, confirmatory Phase II trial using the same combination of REOLYSIN(R) and carboplatin/paclitaxel for patients with head and neck cancers is currently underway in the U.S. Interim results from both the U.K. and the U.S. study formed the basis of the Phase III pivotal program now being developed for REOLYSIN(R) in combination with carboplatin/paclitaxel in this patient population.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Compan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... in water with ultrasound and they,ll spin around their ... yet knows exactly. But researchers at the National Institute ... it,s fast. At up to 150,000 revolutions per minute, ... object submerged in liquid ever reported. , The discovery ... that they could be used not only for moving ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Automated cell ... and maintenance of cell culture. They allow production of ... needs of researchers in drug discovery and industries and ... in mAb production, iPSC research, cryobanking, cell-based assays, and ... contamination risk. , Analysts forecast the Global Cell ...
(Date:7/22/2014)... (NASDAQ: NEOG ) announced today that revenues ... increased 19% from the previous year to $247,405,000. Fiscal ... year,s $27,190,000. Adjusted for a 3-for-2 stock split effective ... year were $0.76, compared to $0.75 a year ago. ... year established new all-time highs for the 32-year-old company. ...
(Date:7/22/2014)... PITTSBURGH , July 22, 2014 ... maker of MD-Cu 29 antimicrobial copper announces Pullman ... to the first EPA-registered antimicrobial solid touch surface, at ... than 99.9% of MRSA, E-coli and other bacteria within 2 ... hospital in protecting against bacteria and infectious diseases in ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 2Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 3Global Cell Culture Market to Grow at 10.27% CAGR by 2018 Forecasts a New Research Report ReportsnReports.com 4Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... Mich., Sept. 10 The primary objective of ... the delivery of,biomedical advances to the marketplace. ... at Boston University on,Friday, September 7th with noted ... Presidents of both Boston,University and Fraunhofer Gesellschaft. ...
... by prominent,Board members Robert Windom, M.D. and Steven ... with inventor Dr. Budimir Drakulic -,have this day ... approved, ambulatory 12-lead ECG cardiovascular,monitor. In private ... ten,days, the trio of cardiovascular experts and Signalife,s ...
... (Amex: PTN ) today announced it has ... melanocortin agonist drug,candidate for the treatment of male ... King Pharmaceuticals Inc. (NYSE: KG ). ... development,and marketing agreement on bremelanotide, with King exercising ...
Cached Biology Technology:'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 3Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 2Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 3
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... NY -- Stem cells offer much promise for treating ... stem cell survival is poor, limiting their effectiveness. New ... survival and optimize their therapeutic function after transplantation, as ... Access , a peer-reviewed journal from Mary Ann Liebert, ... BioResearch Open Access website . ...
(Date:7/22/2014)... hear that drinking milk helps make their bones strong or that ... the idea that if something is good for us, it must ... Journal of Consumer Research , when children hear about the benefits ... predicted that when food is presented to children as making them ... learning how to read or count, they would conclude the food ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2
... academic, government and industry researchers has completed a first draft ... important first step in accelerating the pace of research on ... that face cassava farmers around the world. Cassava is ... for more than 750 million people each day. Although it ...
... 9 Genencor, a division of Danisco, has ... American Institute of Chemical Engineers (AIChE) for its ... Robert Davis, Chair of the AIChE Awards committee, ... Marketing Director, Biomass Enzymes and Accellerase® Product Manager, ...
... A chemical culprit responsible for the rapid, mysterious death ... found by collaborating scientists at Rutgers University and the ... may hold unexpected promise in cancer research. The ... in a virus that has been attacking and killing ...
Cached Biology News:Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4
1M stock solution (238mg/ml)...
...
Request Info...
... peptide derived from the C-terminal region catalytic ... C zeta isoform (PKCzeta). Specificity: Reacts ... Recognizes PKCzeta and PKMzeta (PKCzeta II) ... Reactivity: Mouse Rat (positive controls: mouse and ...
Biology Products: